Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

703.26
-15.1000-2.10%
Post-market: 702.32-0.9400-0.13%18:32 EST
Volume:1.01M
Turnover:711.01M
Market Cap:73.91B
PE:16.91
High:724.13
Open:723.69
Low:701.75
Close:718.36
52wk High:800.99
52wk Low:476.49
Shares:105.10M
Float Shares:103.30M
Volume Ratio:1.00
T/O Rate:0.97%
Dividend:3.52
Dividend Rate:0.50%
EPS(TTM):41.59
EPS(LYR):40.90
ROE:15.19%
ROA:6.16%
PB:2.39
PE(LYR):17.20

Loading ...

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
1 hour ago

Regeneron Pharmaceuticals Currently Down Eight Consecutive Days, on Track for Longest Losing Streak Since May 2018 -- Data Talk

Dow Jones
·
6 hours ago

BUZZ-Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug

Reuters
·
Yesterday

BRIEF-Regeneron Pharmaceuticals Says Lynozyfic Monotherapy In Newly Diagnosed Multiple Myeloma Shows Impressive Responses

Reuters
·
Yesterday

Lynozyfic™ (Linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (Ndmm) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

THOMSON REUTERS
·
Yesterday

Regeneron Hosts Virtual Investor Event on Multiple Myeloma Program

Reuters
·
Yesterday

Regeneron's experimental therapy combo effective in untreated cancer patients

Reuters
·
Dec 06

Regeneron Pharma Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 05

Canaccord Genuity Adjusts PT on Regeneron Pharmaceuticals to $1,057 From $850, Maintains Buy Rating

MT Newswires Live
·
Dec 04

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Dec 04

Regeneron Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
Dec 04

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EST on 2025-12-03

Reuters
·
Dec 04

Sanofi and Regeneron win EU approval for Dupixent in chronic spontaneous urticaria

Reuters
·
Dec 04

Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says

MT Newswires Live
·
Dec 03

Regeneron Pharma Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Dec 03

Regeneron Pharmaceuticals Inc. Stock Sheds 3.9%, Underperforms Market

Dow Jones
·
Dec 02

Vaccine Stocks Falls as FDA Vows to Impose New Vaccine Requirements

Tiger Newspress
·
Dec 01

BRIEF-Regeneron And Tessera Therapeutics To Jointly Develop TSRA-196

Reuters
·
Dec 01

Regeneron and Tessera Partner to Develop Gene Therapy for Alpha-1 Antitrypsin Deficiency

Reuters
·
Dec 01

Regeneron and Tessera Therapeutics to Jointly Develop Tsra-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS
·
Dec 01